Management of Atheromatous Changes in the Abdominal Aorta with Mild Stenosis

Initial Management Approach

The European Heart Journal recommends implementing optimal cardiovascular risk management to reduce major adverse cardiovascular events (MACE) in patients with aortic atheromatous disease 1, 2
Regular follow-up is essential to monitor for progression of atheromatous disease, with assessment of cardiovascular risk factors and treatment compliance at least yearly, as recommended by the European Heart Journal 1
Routine revascularization is not recommended for asymptomatic mild stenosis (42.86%) as it presents no benefit and may increase procedural risks, according to the European Heart Journal 1, 3

The European Heart Journal suggests intensive lipid management should be implemented with a target LDL-C below 1.4 mmol/L (55 mg/dL) to prevent progression of atheromatous disease 1, 2
Single antiplatelet therapy (SAPT) is recommended if there is evidence of prior embolic events, but anticoagulation or dual antiplatelet therapy (DAPT) are not recommended for aortic plaques as they increase bleeding risk without proven benefit, as stated by the European Heart Journal 1, 2
Beta blockers should be considered to reduce aortic wall stress, targeting systolic blood pressure below 120 mmHg and heart rate at or below 60 beats per minute in acute settings, or below 140/90 mmHg for chronic management, according to Praxis Medical Insights 4

The European Heart Journal recommends duplex ultrasound (DUS) for regular surveillance of the abdominal aorta 5
For mild atheromatous changes without aneurysmal dilation, DUS surveillance every 3 years is appropriate, as suggested by the European Heart Journal 5
If the aortic diameter is ≥25 mm and <30 mm, DUS surveillance should be considered every 4 years in patients with life expectancy >2 years, according to the European Heart Journal 5
If DUS does not allow adequate measurement, cardiovascular computed tomography (CCT) or cardiovascular magnetic resonance (CMR) is recommended by the European Heart Journal 5

Assessment for underlying genetic disorders should be considered, as aortic disease may be associated with conditions like Marfan syndrome, Loeys-Dietz syndrome, or familial aortic aneurysm syndromes, as recommended by Praxis Medical Insights 4
Fluoroquinolones should generally be avoided in patients with aortic disease due to increased risk of aortic aneurysm, according to the European Heart Journal and Praxis Medical Insights 4, 5
Lifestyle modifications including smoking cessation, regular moderate physical activity, and avoidance of competitive sports and isometric exercises are recommended by Praxis Medical Insights 4

Do not initiate vasodilator therapy before heart rate control is achieved, as this can cause reflex tachycardia that increases aortic wall stress, as cautioned by Praxis Medical Insights 4
A negative chest x-ray should not delay definitive aortic imaging in patients at high risk for aortic complications, according to Praxis Medical Insights 4
Beta blockers should be used cautiously in the setting of acute aortic regurgitation as they may block compensatory tachycardia, as warned by Praxis Medical Insights 4